MedCity News

Neurogene's Rett syndrome gene therapy has preliminary data supporting safety and efficacy of the one-time treatment. But a late-breaking report of a serious complication in a patient who received the high dose sent shares of the biotech downward.

Fort Health's $5.5 million in funding was led by Twelve Below and Vanterra and included participation from Redesign Health, Blue Venture Fund and True Wealth Ventures.

Experts agree that the incoming Trump administration will likely shake things up in the prescription drug world — most notably when it comes to research and development, drug pricing and PBM reform.

The market opportunities for Medicare Advantage remain vast, but only for those willing to evolve. Now is the time for health plans to step up and embrace the tools and strategies that will not only meet regulatory demands, but also drive innovation in care delivery.

Are you a self-insured employer looking for ways to reduce healthcare spend? Join us for a webinar on December 11 in which HR executives will share their insights.

The convergence of Trump's political capital, Kennedy's agricultural vision, and existing technological capabilities creates an unprecedented opportunity to restructure America's approach to health and disease prevention.

Bariatric surgery is still the gold standard for morbid obesity treatment, yet patients and medical professionals will likely seek less invasive weight loss drugs before considering bariatric surgery.

Johnson & Johnson is suing the federal agencies overseeing the 340B program that makes discounted medicines more accessible to uninsured and underserved patients. J&J contends the Health Resources Services Administration can't legally oppose its plan to implement a new rebate plan for certain 340B drugs.

High labor costs remain an ongoing problem threatening providers' bottom lines, according to new data from Kaufman Hall. The research revealed that medical groups' median investment in each employed physician has reached more than $300,000 for the first time.

There has been a surge in digital mental health solutions, making it difficult to know which ones are effective. One Optum exec weighed in on how she's managing this challenge.